Join us on Thursday July 30th from 9:30 a.m.–4:50 p.m. ET for a Public Meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee discussing Replimu

Join us on Thursday July 30th from 9:30 a.m.–4:50 p.m. ET for a Public Meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee discussing Replimune’s BLA for vusolimogene oderparepvec, in combination with nivolumab, for advanced melanoma.